Convalescent Plasma for the Treatment of Severe SARS-CoV-2 (COVID-19)
Status:
Not yet recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Convalescent plasma has been used for over 100 years in the treatment of severe acute
respiratory infections of viral origin. There are not pharmacological treatments for the
actual outbreak for SARS-Cov-2 and it is necessary to evaluate the efficacy of treatment
options, including convalescent plasma transfusion. The hypothesis is that convalescent
plasma is efficacious and safe for reducing mortality in patients with COVID-19 treated in
ICU
Phase:
Phase 3
Details
Lead Sponsor:
Hospital San Vicente Fundación
Collaborators:
Clínica Cardiovid Clínica Las Américas Clínica León XIII Clínica Rosario El Tesoro Clínica Universitaria Bolivariana Grupo de Inmunodeficiencias primarias Universidad de Antioquia Hospital Pablo Tobón Uribe